IN2014DN02346A - - Google Patents
Info
- Publication number
- IN2014DN02346A IN2014DN02346A IN2346DEN2014A IN2014DN02346A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A IN 2346DEN2014 A IN2346DEN2014 A IN 2346DEN2014A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A
- Authority
- IN
- India
- Prior art keywords
- dosage forms
- oral dosage
- compositions
- enylamino
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530516P | 2011-09-02 | 2011-09-02 | |
| PCT/IB2012/054502 WO2013030803A1 (fr) | 2011-09-02 | 2012-08-31 | Sel de choline d'un composé anti-inflammatoire à base de cyclobutènedione substitué |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN02346A true IN2014DN02346A (fr) | 2015-05-15 |
Family
ID=47116123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2346DEN2014 IN2014DN02346A (fr) | 2011-09-02 | 2012-08-31 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9018261B2 (fr) |
| EP (2) | EP3287438A1 (fr) |
| JP (3) | JP2014529621A (fr) |
| KR (1) | KR102024955B1 (fr) |
| CN (1) | CN103842330B (fr) |
| BR (1) | BR112014004963A2 (fr) |
| CA (1) | CA2846510C (fr) |
| EA (1) | EA201490552A1 (fr) |
| ES (1) | ES2655942T3 (fr) |
| HU (1) | HUE035751T2 (fr) |
| IN (1) | IN2014DN02346A (fr) |
| MX (1) | MX359259B (fr) |
| NO (1) | NO2679622T3 (fr) |
| PL (1) | PL2760821T3 (fr) |
| PT (1) | PT2760821T (fr) |
| SI (1) | SI2760821T1 (fr) |
| WO (1) | WO2013030803A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| EP2764866A1 (fr) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibiteurs de l'enzyme activant nedd8 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| CN111867579B (zh) | 2018-01-08 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3123511A1 (fr) | 2018-12-20 | 2020-06-25 | Novartis Ag | Schema posologique et combinaison pharmaceutique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione |
| WO2020165834A1 (fr) | 2019-02-15 | 2020-08-20 | Novartis Ag | Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations |
| CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| WO2021260528A1 (fr) | 2020-06-23 | 2021-12-30 | Novartis Ag | Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506252A (en) | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| DK0796243T3 (da) | 1994-11-16 | 1999-09-13 | American Home Prod | Diaminocyclobuten-3,4-dioner |
| US5840764A (en) | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AU6250298A (en) | 1997-01-30 | 1998-08-25 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| FR2815345B1 (fr) | 2000-10-12 | 2002-12-13 | Servier Lab | Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0028844D0 (en) | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
| JP2004521106A (ja) | 2001-01-16 | 2004-07-15 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| EP1357909B1 (fr) | 2001-01-16 | 2009-01-07 | Smithkline Beecham Corporation | Antagonistes des recepteurs d'il-8 |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| WO2002062761A1 (fr) | 2001-02-07 | 2002-08-15 | Abbott Laboratories | Diones aminales utilisees en tant qu'agents d'ouverture des canaux potassiques |
| KR20030088044A (ko) | 2001-03-30 | 2003-11-15 | 스미스클라인 비참 코포레이션 | 페놀-함유 화합물의 합성 방법 |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| RU2344123C9 (ru) | 2001-04-16 | 2009-05-20 | Шеринг Корпорейшн | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора |
| WO2003000245A1 (fr) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Composes destines a etre utilises dans des troubles associes a l'activite des mastocytes ou des basophiles |
| EP1485089B1 (fr) | 2002-03-18 | 2013-04-17 | Merck Sharp & Dohme Corp. | Traitements combines pour maladies induites par la chimiokine |
| WO2005004915A2 (fr) * | 2003-07-09 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Compositions contenant meloxicam |
| US20050192345A1 (en) | 2004-01-30 | 2005-09-01 | Schering Corporation | Crystalline polymorphs of a CXC-chemokine receptor ligand |
| JP2007522217A (ja) * | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
| US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| GB0407908D0 (en) * | 2004-04-07 | 2004-05-12 | Univ York | Ionic liquids |
| DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| ATE432921T1 (de) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer wirkung |
| DE102005001053A1 (de) | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| EP1851277B1 (fr) | 2005-02-10 | 2008-12-10 | Wacker Chemie AG | Vernis contenant des particules presentant des groupes isocyanate proteges |
| CN101203509B (zh) | 2005-02-16 | 2013-05-08 | 默沙东公司 | 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶 |
| DE102005035741A1 (de) | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| AU2007269572A1 (en) | 2006-07-07 | 2008-01-10 | Pharmacopeia, Inc. | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| US7691851B2 (en) | 2007-03-07 | 2010-04-06 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| CA2689581A1 (fr) | 2007-06-06 | 2008-12-11 | Novartis Ag | Composes de cyclobutenedione substitues anti-inflammatoires |
| CA2692269A1 (fr) | 2007-07-03 | 2009-01-08 | Schering Corporation | Procede et intermediaires de synthese de composes de 3,4-dioxo-1-cyclobutene 1,2-substitues |
| US20100249439A1 (en) | 2007-07-05 | 2010-09-30 | Vincenzo Liotta | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| WO2009012375A2 (fr) | 2007-07-19 | 2009-01-22 | Wyeth | Inhibiteurs de la squarate kinase |
| MX2010006089A (es) | 2007-12-04 | 2010-09-22 | Schering Corp | Metodos de tratamiento de enfermedad pulmonar obstructiva cronica. |
| AU2008334629B2 (en) | 2007-12-10 | 2012-04-12 | Novartis Ag | Organic compounds |
| JP2011526888A (ja) * | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| WO2010017051A1 (fr) | 2008-08-04 | 2010-02-11 | Merck Serono S.A. | Nouveaux composés phénylamino isonicotinamides |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| EP2376065A2 (fr) * | 2008-11-14 | 2011-10-19 | Portola Pharmaceuticals, Inc. | Composition solide pour libération contrôlée d'agents actifs ionisables avec une faible solubilité aqueuse à ph bas, et procédés d'utilisation associés |
| WO2010063802A1 (fr) | 2008-12-05 | 2010-06-10 | Novartis Ag | Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2 |
| WO2010091543A1 (fr) | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'hydrazinocyclobut-3-ène-1,2-dione comme antagonistes de cxcr2 |
-
2012
- 2012-08-31 ES ES12780535.6T patent/ES2655942T3/es active Active
- 2012-08-31 JP JP2014527801A patent/JP2014529621A/ja active Pending
- 2012-08-31 EA EA201490552A patent/EA201490552A1/ru unknown
- 2012-08-31 CA CA2846510A patent/CA2846510C/fr not_active Expired - Fee Related
- 2012-08-31 IN IN2346DEN2014 patent/IN2014DN02346A/en unknown
- 2012-08-31 HU HUE12780535A patent/HUE035751T2/hu unknown
- 2012-08-31 EP EP17191365.0A patent/EP3287438A1/fr not_active Withdrawn
- 2012-08-31 PL PL12780535T patent/PL2760821T3/pl unknown
- 2012-08-31 SI SI201231173T patent/SI2760821T1/en unknown
- 2012-08-31 CN CN201280047528.3A patent/CN103842330B/zh not_active Expired - Fee Related
- 2012-08-31 KR KR1020147008317A patent/KR102024955B1/ko active IP Right Grant
- 2012-08-31 EP EP12780535.6A patent/EP2760821B1/fr not_active Not-in-force
- 2012-08-31 MX MX2014002492A patent/MX359259B/es active IP Right Grant
- 2012-08-31 US US14/241,306 patent/US9018261B2/en not_active Expired - Fee Related
- 2012-08-31 BR BR112014004963A patent/BR112014004963A2/pt active Search and Examination
- 2012-08-31 WO PCT/IB2012/054502 patent/WO2013030803A1/fr active Application Filing
- 2012-08-31 PT PT127805356T patent/PT2760821T/pt unknown
-
2013
- 2013-06-26 NO NO13173884A patent/NO2679622T3/no unknown
-
2016
- 2016-09-08 JP JP2016175348A patent/JP6612200B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-19 JP JP2018135448A patent/JP2019001787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014002492A (es) | 2014-05-28 |
| ES2655942T3 (es) | 2018-02-22 |
| JP2014529621A (ja) | 2014-11-13 |
| PL2760821T3 (pl) | 2018-04-30 |
| WO2013030803A1 (fr) | 2013-03-07 |
| CA2846510C (fr) | 2019-10-22 |
| JP2017025081A (ja) | 2017-02-02 |
| US20140206768A1 (en) | 2014-07-24 |
| KR102024955B1 (ko) | 2019-09-24 |
| SI2760821T1 (en) | 2018-02-28 |
| PT2760821T (pt) | 2018-01-11 |
| KR20140059264A (ko) | 2014-05-15 |
| JP6612200B2 (ja) | 2019-11-27 |
| MX359259B (es) | 2018-09-20 |
| EP2760821B1 (fr) | 2017-10-11 |
| CA2846510A1 (fr) | 2013-03-07 |
| EP2760821A1 (fr) | 2014-08-06 |
| BR112014004963A2 (pt) | 2017-03-21 |
| NO2679622T3 (fr) | 2018-01-20 |
| EP3287438A1 (fr) | 2018-02-28 |
| CN103842330A (zh) | 2014-06-04 |
| HUE035751T2 (hu) | 2018-08-28 |
| EA201490552A1 (ru) | 2014-11-28 |
| JP2019001787A (ja) | 2019-01-10 |
| US9018261B2 (en) | 2015-04-28 |
| CN103842330B (zh) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN02346A (fr) | ||
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| IN2014MN00988A (fr) | ||
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| GT201400016A (es) | Indazoles | |
| IN2014MN00948A (fr) | ||
| UA111770C2 (uk) | Інгібітори бромдомену | |
| CA2818187C (fr) | Inhibiteurs de bromodomaines et leurs utilisations | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| WO2012116290A3 (fr) | Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant | |
| IN2014MN00987A (fr) | ||
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| MX2012006730A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas. | |
| WO2011127333A3 (fr) | Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques | |
| CR20140134A (es) | Composiciones farmacéuticas | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| TR201901114T4 (tr) | Özgün immünomodülatör ve anti inflamatuvar bileşikler. | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| WO2013170012A3 (fr) | Formulations de testostérone proliposomales | |
| BR112013029730A2 (pt) | composição farmacêutica de rosuvastatina cálcica | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias |